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Purpose.Theaimofthispaper isto developnewopticalbioprobes fortheimagingofapoptosis.Procedure. Wedeveloped quenched
near-infraredprobes whichbecomeﬂuorescentuponcleavagebycaspase-3,thekeyregulatory enzymeofapoptosis.Results.Pr obes
were shown to be selectively cleaved by recombinant caspase-3. Apoptosis of cultured endothelial cells was associated with an
increased ﬂuorescent signalfor the cleaved probes, which colocalized with caspase-3 andwas reduced by the addition of a caspase-
3 inhibitor. Flow cytometry demonstrateda similarproﬁle between the cleaved probes andannexin V. Ex vivo experiments showed
thatsections ofhearts obtained from mice treated with the proapoptotic drug doxorubicin displayed an increase in the ﬂuorescent
signalfor the cleaved probes, which was reduced by a caspase-3inhibitor. Conclusion. We demonstrated the capacity of these novel
probes to detect apoptosis by optical imaging in vitro and ex vivo.
1.Introduction
Apoptosis, or programmed cell death, is a well-organized
mechanism that allowscells todie without leading to inﬂam-
mation, contrary to necrosis [1, 2]. Apoptosis plays a critical
role in a number of physiological functions such as fetal
development or tissue homeostasis regulation [3]. In addi-
tion to these physiological roles, considerable evidence
suggests that changes in apoptosis play a major role in the
development of various diseases. Indeed, in cancer, inhibi-
tion ofapoptosis leadsto anarchic division ofcells and favors
tumor development. In contrast, overactivation of apoptosis
contributes to the aggravation of various cardiovascular
diseases such as atherosclerosis, myocardial, infarction, and
heart failure [4].
Over the past years, many methods have been developed
to detect apoptosis, most of them targeting phosphatidylser-
ine (PS) which is normally expressed on the inner plasma
membrane. However, in apoptotic conditions, aminophos-
pholipid translocase inhibition and scramblase activation
lead to PS translocation to the outer leaﬂet of the plasma
membrane[5,6].Thus,PSbecomeseasilyaccessibletodetect
apoptosis [7]. Noninvasive imaging methods targeting PS
have been developed. Indeed, natural ligands of this phos-
pholipid, annexin V or the C2A domain of synaptotagmin
[8], have been labeled with radioisotopes (99mTc) for single2 International Journal of Molecular Imaging
photon emission computed tomography imaging [9, 10],
withmagneticnanoparticlesformagneticresonanceimaging
[11], or with near-infrared ﬂuorescent labels for optical
imaging [12].
Despite this wide availability of biomarkers that use PS
for imaging of apoptosis, this approach suﬀers from several
limitations. Indeed, necrosis induces degradation of cell
membrane and, thus, exposition of PS to labeled annexin V
or synaptotagmin, leading to a false positive signal [13].
Because of these limitations of the currently available meth-
ods for apoptosis imaging, there is a clear need for new
methodsbasedonsmartprobesthattargetspeciﬁcmolecular
events related to the apoptosis phenomenon.
Two major pathways compose apoptosis. The ﬁrst one
is extrinsic signaling, or death receptor-mediated pathway.
The second one is the intrinsic, mitochondrial-dependent
pathway, which is activated in response to extracellular
stimuli or DNA damage [14]. Both pathways, however,
commonly involve activation of cysteinyl-aspartate-speciﬁc
proteases, or caspases, and especially require activation (by
cleavage)ofcaspase-3 [15,16].Becauseofitscentralposition
on major apoptosis pathways, activated caspase-3 is a target
of choice for the detection of programmed cell death both
in vitro and in vivo and has already been chosen to image
(noncardiac) apoptosis in various models [17–20].
Thus, the purpose of the present study is to develop
and validate new FRET-based smart molecular probes for
the detection of apoptosis, based on their ability to emit
near-infrared ﬂuorescence signal upon selective cleavage by
activated caspase-3.
2.MaterialandMethods
2.1. In Vitro Cleavage of Probes by Recombinant Caspases.
Recombinant caspases were incubated in buﬀer (100mM
N a C l ,4 0m MH E P E S ,1 0m MD T T ,1m ME D T A ,1 0 %( w / v )
sucrose, and 0.1% (w/v) CHAPS, pH 7.4) for 75min at
37◦C. The ﬁnal concentration of each caspase was adjusted
to obtain a volumic activity of 0.5pmol/min/μLi nt h e
well. The caspase-activatable probe was then added (ﬁnal
concentration: 1μM), and the kinetics of cleavage in each
condition was monitored at 37◦C for 5h on the FlexStation
II microplate reader: ﬂuorescence emission was recorded
at 670nm every 60 seconds with an excitation wavelength
set at 645nm. In some wells, the caspase-3 and caspase-7
inhibitor Ac-Asp-Glu-Val-Asp-CHO was added at a ﬁnal
concentration of 0.25μMa n di n c u b a t e da t3 7 ◦Cf o r6 0m i n
before probes addition.
2.2. Cells Line and Culture Conditions. Murine heart micro-
vascularendothelialcells(HME)were culturedinDulbecco’s
modiﬁed eagle’s medium (DMEM) enriched with 4.5g·L−1
glucose and supplemented with 1% glutamine, 10% fetal
bovine serum (FBS), 50units/mL penicillin, and 50μg/mL
streptomycin. Cells were grown at 37◦Ci nah u m i d i ﬁ e d
95% O2-5% CO2 atmosphere. After being starved from
growth factors, using (FBS 2%), cells were incubated with
solvent or staurosporine at 1μM, for 6h, in order to induce
apoptosis [21]. Staurosporine-treated cells were treated or
not with the caspase-3 inhibitor (Z-Asp(OMe)-Gln-Met-
Asp(OMe)-CH2F) which was purchased from Calbiochem
(San Diego, CA, USA) [22].
2.3. Evaluation of Caspase-3 Activity. Caspase-3 activity was
evaluated in HME cells cultured in 96 well plates (around
10000 cells/well) which were seeded and treated as describe
above. Cells were then incubated with a caspase 3/7 glow
kit (Promega) for 30min, and the luminescence signal was
read using a Mithras Multimode Microplate Reader LB 940
(Berthold Tech, Thoiry, France).
2.4. Evaluation of Probe Fluorescence in Cell Lysates. HME
cells seeded in a 10cm Petri dish were scrapped in cold
caspase-3 buﬀer and incubated with the probe (1μM) at
37◦C. The ﬂuorescence signal was then followed over 6h
using a FlexStation II (Bucher Biotec).
2.5. Evaluation of Probes Penetration in Cells. HME cells
seeded in 6 well-dishes were incubated with the probe
for 1 hour, in caspase-3 buﬀer, after which the super-
natant (cell medium) was removed, and the cells were
trypsinised and lysed. Both the cell medium and the cell
lysateswere incubatedovernightwithrecombinantcaspase-3
(0.5pmol/min/μL)at37◦C.Fluorescencewasreadwith aﬂu-
orescent microplate spectrometer. The penetration of probes
was assessed using the ratio of cell/medium ﬂuorescence.
2.6. Flow Cytometry Analysis. Flow cytometry analysis of the
probesor annexin V was performed in HMEcells seeded in a
10cm Petri dish. Then, cells were trypsinized and incubated
with 10μL/mL annexin V (Beckton Dickinson) or 1μM
probe for 15min at room temperature in a dark atmosphere.
Analysis was carried out using a Becton Dickinson FACScan
ﬂow cytometer (Mountain View, CA). Results were analyzed
using FlowJo software (Tree Star, Ashland, USA). Only cells
with an FL4 ﬂuorescence intensity between 102 to 104 were
included in the analysis gate.
2.7. Fluorescence Microscopy. HME cells were cultured in 8-
well slide chambers (Labtek; Becton Dickinson, Lane Cove,
New South Wales, Australia). After treatment, cells were
rinsed with phosphate buﬀered saline (PBS) 1X, followed
by ﬁxation with cold methanol for 10min at −20◦C. Cells
were then saturated in PBS 1X/bovine serum albumin 1%,
overnight, afterwhich theywere rapidly washed with PBS1X
and incubated with a rabbit mAb against cleaved (activated)
caspase-3 (1:100, cell signaling) at room temperature for
1h. After washing with PBS 1X, cells were incubated
with a Cy 3.0-labeled donkey antirabbit IgG Ab (1:100;
Jackson Immunoresearch) and with Bisbenzimide H33342
(Hoechst, Riedel-de Ha¨ en) at 0.1μg/mL for 2min. In some
experiments, slides were also incubated with 1μMp r o b ef o r
2h at 37 ◦C. Coverslips were rapidly rinsed and mounted
in VECTASHIELD ﬂuomounting medium (Vector) and
observed using an Axio Imager Z.1 ﬂuorescence microscopeInternational Journal of Molecular Imaging 3
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Figure 1: (a) Typical ﬂow cytometry signal obtained in HME cells. Cells were either untreated (control) or incubated with staurosporine
1μM for6h, andpercentage ofcell death, derived from the ﬂow cytometry analysis,obtained in controlor staurosporine-treated HME cells.
Data are mean ± SEM (n = 30). (b) Caspase-3 activity in HME cells. Cells were either untreated (control) or treated with staurosporine in
the absence orthe presence of the caspase-3 inhibitorZ-Asp(OMe)-Gln-Met-Asp(OMe)-CH2F (100μM).R.L.U.: relative luminescentunits.
Data are mean ± SEM (n = 6). ∗∗P<. 01 versus controls; †P<. 05 versus staurosporine alone.
equipped with ApoTome technology (Zeiss, Oberkochem,
Germany).
2.8. Animal Model of Apoptosis. Cardiac apoptosis induced
by doxorubicin (DOX) as previously described. [23, 24].
For this purpose, 8-week-old C57BL6/J male mice (Janvier)
received an intraperitoneal injection of 20mg/kg DOX
(Sigma). Four days later, mice were euthanized by cervical
dislocation, the heart was excised, and the left ventricle (LV)
was frozen until analysis. These in vivo experiments followed
the institutional and national guide for the care and use of
laboratory animals.
In order to assess the possible eﬀects of the treatment
on cell integrity, 4μM section were obtained from frozen
LV using a cryotome. Sections were ﬁxed in acetone for
30s then rinsed in PBS 1X. Structure integrity was assessed
with 5.0μg/mL of wheat germ agglutine conjugated with
ﬂuorescein (Invitrogen) for 30min. Nuclei were counter-
stainedwithBisbenzimideH33342(HoechstRiedeldeHa¨ en)4 International Journal of Molecular Imaging
QCASP3.2
2
QSY21
OH
N
N
N
O
Gly-Arg2-Ala-Arg5
QCASP4.1
N
N
N
N
H
O
O
N
H
O
O
O
QCASP5.1
HN
HN
QSY 21
QSY 21
Cy5
Ac-Cys-Asp-Glu-Val-Asp-Lys-NH
−
OH Gly-Arg2-Ala-Arg5
Cy5
Cy5
Ahx-Lys-Asp-Glu-Val-Asp-Lys NH2
Ahx-Lys-Asp-Glu-Val-Asp-Lys NH2
Figure 2: Chemical structure of QCASP3.2, QCASP4.1, and
QCASP5.1.
at 0.1μg/mL for 2min. Sections were analyzed using an
Axio Imager Z.1 ﬂuorescence microscope equipped with
ApoTome technology (Zeiss, Oberkochem, Germany).
2.9. Evaluation of Caspase-3 Activity in Mouse LV. Frozen LV
were homogenized in 200μL ice-cold caspase-3 buﬀer, and
homogenates were then centrifuged for 5min, at 12000rpm,
and the amount of proteins present in the supernatant was
evaluated using a Bradford assay. All samples were then
dilutedto 2 mg ofprotein/mL, incubated for 30min with the
same volume of caspase 3/7 glow kit, and the luminescence
signal was read using a Mithras Multimode Microplate
Reader LB 940.
2.10. Evaluation of Probes Fluorescence in Mouse LV Lysates.
Frozen LV were homogenized and diluted as describe above.
Samples were then incubated with 5μMp r o b ea t3 7 ◦C,
and the ﬂuorescence signal was followed over 6h, using a
FlexStation II (Bucher Biotec).
2.11. Evaluation of Probes Fluorescence in Mouse Thick LV
Sections. Fresh LVwasslicedin1mmsectionsandincubated
with PBS or with the caspase-3 inhibitor Z-Asp(OMe)-Gln-
Met-Asp(OMe)-CH2F (100μM) for 30min, after which the
sections were incubated with the probe (1μM) for 1h.
Fluorescence of the slices was analyzed using an infrared
imaging system, Odissey (LI-COR Bioscience).
2.12. Colocalization of Probe Fluorescence with Caspsase-3 in
LV Sections. Frozen LV were sliced in 4μms e c t i o nu s i n ga
cryotome. Sections were ﬁxed in acetone for 30s then rinsed
in PBS 1X. Fluorescence emitted by the cleaved probe as
well as that of the anticaspase-3 antibody were analyzed as
described above for cultured cells.
2.13. Statistical Analysis. Results were expressed as means
± SEM. Data were analyzed using either Student’s t-test
or by one-way or two-way ANOVA, eventually followed by
Student’s t-test with Bonferroni correction. A P value <.05
was considered to be statistically signiﬁcant.
3.Results
3.1. Validation of the In Vitro Model of Apoptosis. Apoptosis
was induced in vitro by incubating heart microvascular
endothelial (HME) cells with 1μM staurosporine for 6h.
Cell death, assessed by ﬂow cytometry analysis, is shown
in Figure 1. Compared to control cells, staurosporine-
treated cells displayed a ﬂow cytometry proﬁle charac-
teristic of increased cell death (Figure 1(a)). Quantitative
analysis of the scatter plot revealed that staurosporine
markedly (almost 6 times) and signiﬁcantly increased
cell mortality (Figure 1(a)). Figure 1(b) shows that stau-
rosporine more than doubled caspase-3 activity compared
to control cells. Moreover, incubation of the cells with
Z-Asp(OMe)-Gln-Met-Asp(OMe)-ﬂuoromethylketone (Z-
Asp(OMe)-Gln-Met-Asp(OMe)-CH2F), a speciﬁc inhibitor
of caspase-3, before staurosporine treatment, reduced
caspase-3 activity, which became not signiﬁcantly diﬀerent
from controls.
3.2. Evaluation of the Cleavage Selectivity of QCASP3.2
towards Recombinant Enzymes. QCASP3.2 consists of the
well-known Asp-Glu-Val-Asp caspase-3 tetrapeptide sub-
strate ﬂanked on its N and C termini, respectively, by a
Cysteine and a Lysine, allowing for the attachment of a
Cy5.0 dye and a QSY21 quencher (Figure 2). Speciﬁcity
of QCASP3.2 was studied by assessing its activation in a
presence of a panel of recombinant active caspases (1, 3,
6, 7, 8, and 11). QCASP3.2 is cleaved by caspase-3 and,
to a very small extent, by caspase-7, and both cleavages
weresuppressedbythecaspase-3/caspase7inhibitorAc-Asp-
Glu-Val-Asp-CHO (Figure 3(a)). In contrast, no detectable
cleavage was observed in the presence of caspases 1, 6, 8, and
11 (data not shown).
3.3. Evaluation of the Capacity of QCASP3.2 to Detect
Caspase-3 ActivationIn Vitro. The ﬂuorescence generated by
the cleavage of QCASP3.2 (1μM) incubated with apoptotic
cell lysates over 6h is shown in Figure 3(b).C o m p a r e d
to control cells, staurosporine-treated cells presented an
almost doubled ﬂuorescence level (at 6h: control 2418 ±
508; staurosporine 4532 ± 736R.F.U. × 102; P<. 01). This
increased ﬂuorescence was abolished by a pretreatment
withtheselectivecaspase-3 inhibitorZ-Asp(OMe)-Gln-Met-
Asp(OMe)-CH2F. Indeed, in the presence of the inhibitor,
ﬂuorescence at 6h was reduced to 1357 ± 402R.F.U. × 102
(P<. 01 versus staurosporine alone).
Results on the activation of QCASP3.2 and on the
colocalization with caspase-3 in cultured cells are presented
in Figure 3(c). In control cells, in which little or no activated
caspase-3 staining (red) was observed, we found low activa-
tion of QCASP3.2 (yellow).International Journal of Molecular Imaging 5
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Figure 3: (a) Activation of QCASP3.2 by recombinant caspases. R.F.U.: relative ﬂuorescent units. Cleavage by caspases 3 and 7 in the absence or presence
of the caspase inhibitor Ac-Asp-Glu-Val-Asp-CHO (250nM) is shown. No ﬂuorescence was detected with caspases 1, 6, 8, and 11, thus these data are not
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In contrast to controls, in staurosporine-treated cells,
the increased positive IF staining for activated caspase-3 was
accompanied by a strong increase in the ﬂuorescence signal
emitted by the cleaved QCASP3.2 probe, which was partly
reduced by the caspase-3 inhibitor. Moreover, in those
cells, we observed a colocalization of the antiactivated
caspase-3mAbandcleavedQCASP3.2staining.Additionally,
high resolution examination of the slices revealed that the
ﬂuorescence was intracellular and not membrane-bound,
although this might only partially reﬂect the cell penetration
in this situation because of the experimental conditions
involving methanol ﬁxation of the sections.
Despite the fact that QCASP3.2 brought several promis-
ing results in terms of capacity to be cleaved and to become
highly ﬂuorescent in the presence of activated caspase-3
(eitherrecombinantorendogenous),thisprobedidnotshow
satisfactory cell labeling ability in ﬂow cytometry (data not
s h o w n ) .A st h i si sm o s tl i k e l yd u et oi n s u ﬃcient internaliza-
tion of the probe into cells, we developed second-generation
probes, namely, QCASP4.1 and QCASP5.1 (Figure 2), char-
acterized by the addition of a cell-penetrating peptide (CPP)
to improve the capacity of the probes to penetrate into cells,
and in the case of QCASP5.1, an additional PEG moiety
aimed at increasing peptide half-life for future subsequent in
vivostudies.
3.4. Comparison of the Cell-Penetrating Properties of
QCASP3.2,QCASP4.1,and QCASP5.1. In ordertoassess the
capacity of the probes to penetrate into cells, HME cells
were incubated for 1h with each probe, after which the
cell culture medium (corresponding to the extracellular
compartment) was removed, and the cells were lysed (the
resulting lysate representing the intracellular compartment).
Figure 4(a) (left: penetration index of QCASP probes
in HME cells. The penetration index was deﬁned as the
ratio of ﬂuorescence measured in the cell lysates over that
measured in the cell medium. Data are mean ± SEM
(n = 12). ∗∗P<. 01 versus QCASP3.2; ††P<. 01 versus
QCASP4.1; right: representative image of internalization of
QCASP5.1 in endothelial cells. The scale bar represents a 20-
micrometer length) shows that QCASP4.1 has the highest
capacity to penetrate the cells, followed by QCASP5.1 and
QCASP3.2. Indeed, compared to QCASP3.2, the ratio cell
lysate/cellmediumﬂuorescencewasincreased 15 and5 times
for QCASP4.1 and QCASP5.1, respectively. A representative
image of internalization of QCASP5.1 in endothelial cells is
s h o w ni nF i g u r e4(a).
3.5. Evaluation of the Cleavage Selectivity of QCASP4.1 and
QCASP5.1 towards Recombinant Enzymes (Figure 4(b)).
Recombinant caspase-3 assays were performed similarly to
QCASP3.2 with the second-generation probes and showed
an expected increase of ﬂuorescence as a function of time
(Figure 4(b): activation of QCASP4.1 and QCASP5.1 by
recombinant caspases. R.F.U.: relative ﬂuorescent units.
Cleavage by caspases 3 and 7, with or without the caspase-
3/7 inhibitor Ac-Asp-Glu-Val-Asp-CHO (250nM) is shown.
Noincreased ﬂuorescencewas detectedeitherinthepresence
ofcaspases 1, 6,8, and 11,thusthese dataare notrepresented
on the ﬁgure). However, the ﬁnal level of ﬂuorescence
(i.e., after reaching steady state) was lower with both cell
penetrating probes QCASP4.1 and QCASP5.1 than with
QCASP3.2. Despite this, QCASP4.1 and QCASP5.1 were
found to be eﬃciently cleaved by the target enzyme. In fact,
results obtained with cleavage of QCASP4.1 and QCASP5.1
by a series of recombinant caspases (1, 3, 6, 7, 8, and 11)
demonstrated a signiﬁcant cleavage only observed in the
presence of caspases 3 and 7 (Figure 4(b)), and no cleavage
induced by caspases 1, 6, 8, and 11 (data not shown). In
parallel we also found an abolition of the cleavage induced
by caspase 3 or 7 in the presence of the nonselective caspase
inhibitor Ac-Asp-Glu-Val-Asp-CHO.
3.6.Evaluationof theCapacity ofQCASP4.1and QCASP5.1to
Detect Endogenous Caspase-3 Activity In Vitro. The capacity
of QCASP4.1 and QCASP5.1 to detect caspase-3 activity was
alsoassessed instaurosporine-treated HMEcells.Speciﬁcally,
we analyzed the kinetics of probe activation by cell lysates,
and the colocalization of the probe with a monoclonal
antibody (mAb) directed against caspase-3.
Figure 4(c) (activation of QCASP4.1 and QCASP5.1 by
lysates of HME cells. Cells were either untreated (control)
or treated with staurosporine 1μMf o r6 h ,i nt h ea b s e n c e
or the presence of the caspase-3 inhibitor Z-Asp(OMe)-Gln-
Met-Asp(OMe)-CH2F (100μM). R.F.U.: relative ﬂuorescent
units. Data are mean ± SEM (n = 4). ∗∗P<. 01 versus
control and ††P<. 01versus staurosporine alone by repeated
measures ANOVA) shows that activation of QCASP4.1 and
of QCASP5.1by lysates obtained from staurosporine-treated
cells was signiﬁcantly higher compared to control lysates (at
6h: for QCASP4.1: control 298 ± 26; staurosporine 573 ±
17R.F.U. × 102; P<. 01; for QCASP5.1: control 419 ± 43;
staurosporine 886±19R.F.U. × 102; P<. 01). This increased
ﬂuorescence was abolished by the caspase-3 inhibitor Z-
Asp(OMe)-Gln-Met-Asp(OMe)-CH2F (QCASP4.1: 146 ±
23R.F.U. × 102; P<. 01 versus staurosporine alone;
QCASP5.1: 189 ± 30R.F.U. × 102; P<. 01 versus stau-
rosporine alone).
Figure 5 shows the staining obtained from cleaved
QCASP4.1 and QCASP5.1 (yellow) and from the antiac-
tivated caspase-3 mAb (red). While control cells did not
display any detectable activation ofprobes, in staurosporine-
treated cells, the increased positive IF staining for caspase-
3 was accompanied by a strong increase in the ﬂuorescence
signal emitted by cleaved QCASP4.1 and QCASP5.1 probes.
Moreover, in the majority of the cells, we observed a
colocalization of caspase-3 mAb and cleaved QCASP4.1 and
QCASP5.1 staining. Quantitative analysis showed that 94 ±
3% (n = 7) and 74 ± 6% (n = 11) of the cells demon-
strated colocalization of caspase-3 with QCASP4.1 and
QCASP5.1, respectively. Furthermore, the staining obtained
from cleaved probes was markedly reduced by the caspase-3
inhibitor Z-Asp(OMe)-Gln-Met-Asp(OMe)-CH2F.
3.7. Flow Cytometry Analysis of the Comparison between
Annexin V and QCASP4.1 and QCASP5.1 Labeling. HMEInternational Journal of Molecular Imaging 7
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Figure 5: Colocalization of activated QASP4.1- and QCASP5.1-induced ﬂuorescence (yellow) with caspase-3 IF (red) in HME cells. Cells
were either untreated (control) or treated with staurosporine 1μM for 6h, in the absence or the presence of the caspase-3 inhibitor Z-
Asp(OMe)-Gln-Met-Asp(OMe)-CH2F (100μM). Nuclei are stained with Hoechst and appear blue. The orange staining represents the
colocalization of QCASP4.1 or QCASP5.1 (yellow) with caspase-3 mAb (red; magniﬁcationx20).
cells were incubated with annexin V, QCASP4.1, or
QCASP5.1 for 30min, before analysis. Results are shown
in Figure 6.O n l y1 1± 5% of control cells were positive
for annexin V, corresponding to basal level of apopto-
sis in normal cell culture. After staurosporine treatment,
the number of annexin V positive cells was increased
threefold (34 ± 5%; P<. 01), and this was prevented
by pretreatment with the caspase-3 inhibitor Z-Asp(OMe)-
Gln-Met-Asp(OMe)-CH2F( 1 1 ± 3%). These results with
annexin V are quantitatively similar to those obtained for
caspase-3 activity (Figure 1), both in terms of the eﬀect of
staurosporine and caspase-3 inhibitor.
Figure 6 also shows that staurosporine signiﬁcantly
increased the number of cells positive for cleaved QCASP4.1
and QCASP5.1 ﬂuorescence, which also increased by about
threefold compared to control cells (QCASP4.1: control: 8 ±
3%; staurosporine 26 ± 7%; P<. 01; QCASP5.1: control:
9 ± 3%; staurosporine 26 ± 10%; P<. 01), again reinforcing
that both probes are being cleaved by apoptotic cells. In
addition, the caspase-3 inhibitor signiﬁcantly reduced theInternational Journal of Molecular Imaging 9
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Figure 6: Flow cytometry analysisof Annexin V, QCASP4.1,andQCASP5.1 ﬂuorescence in HME cells. Cells were either untreated (control)
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in the analysis gate.
number of staurosporine-treated QCASP4.1 or QCASP5.1-
positive cells (QCASP4.1: 14 ± 5%; P<. 05; QCASP5.1: 9±
4%; P<. 05).
3.8. Evaluation of the Capacity of QCASP5.1 to Detect
Caspase-3 Activity in an Ex Vivo Model of Cardiac Apoptosis.
As shown in Figure 7(a) (caspase-3 activity in the left
ventricle. Mice were either untreated (control) or treated
with an intraperitoneal injection of 20mg/kg DOX four days
before sacriﬁce. Heart sections from DOX mice were either
untreated or treated with the caspase-3 inhibitor Z-Asp-
Gln-Met-Asp-FMK. R.L.U.: relative luminescent Units. Data
are mean ± SEM (n = 6). ∗∗P<. 01 versus controls;
††P<. 05 versus DOX alone), a four-day treatment with
DOX was associated with a twofold signiﬁcant increase in
left ventricular (LV) caspase-3 activity, which was reduced by
the caspase-3 inhibitor Z-Asp(OMe)-Gln-Met-Asp(OMe)-
CH2F.10 International Journal of Molecular Imaging
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Compared to controls, LV lysates from DOX-treated
mice showed a signiﬁcant increase in the ﬂuorescent signal
emitted by cleaved QCASP5.1 (Figure 7(b):a c t i v a t i o no f
QCASP5.1 by LV lysates. Lysates were obtained from mice
either untreated (control) or treated with an intraperitoneal
injection of 20mg/kg DOX four days before sacriﬁce. Lysates
from DOX mice were either untreated or treated with
the caspase-3 inhibitor Z-Asp(OMe)-Gln-Met-Asp(OMe)-
CH2F. R.F.U.: relative ﬂuorescent units. Data are mean ±
SEM (n = 6). ∗∗P<. 01 versus controls; ††P<. 01 versus
DOX alone). In contrast, this increased cleavage was absent
when lysates of DOX mice were incubated with the caspase-
3 inhibitor. In parallel, Figure 7(c) (QCASP5.1 ﬂuorescence
in LV sections. Sections were obtained from mice either
untreated (control) or treated with an intraperitoneal injec-
tion of 20mg/kg DOX four days before sacriﬁce. Sections
from DOX mice were either untreated or treated with
the caspase-3 inhibitor Z-Asp(OMe)-Gln-Met-Asp(OMe)-
CH2F. R.F.U.: relative ﬂuorescent units. Data are mean ±
SEM (n = 6). ∗∗P<. 01 versus controls; †P<. 05 versus
DOX alone) shows that hearts sections obtained from DOX
mice and incubated with QCASP5.1 displayed a signiﬁcant
increase in ﬂuorescence, which was also prevented by the
caspase-3 inhibitor. Finally, histological examination showed
that hearts from DOX-treated hearts displayed a maintained
structural integrity and an absence of detectable necrosis
(Figure 7(d): typical histological image of an LV section
from DOX-treatedmice.LV sections werestained with wheat
germ agglutine conjugated with ﬂuorescein, and nuclei were
counterstained with Bisbenzimide H33342. The scale bar
represents a 50-micrometer length).
4.Discussion
The aim of this study was to develop new probes, targeting
selectively active caspase-3, for noninvasive optical imaging
of apoptosis.
The capacity of the probes to be cleaved selectively
by caspase-3 was ﬁrst evaluated in enzymatic assays using
recombinant caspases. The selected panel included enzymes
from the three main caspases groups, including inﬂam-
matory caspases (1 and 11), initiator caspases (8), and
eﬀector caspases (3, 6, and 7) [25]. Importantly, these three
latter enzymes are known to recognize the Asp-Glu-Val-Asp
sequence incorporated in the structure of the three probes
[26]. We found that none of the probes were cleaved by
caspases 1, 6, 8, and 11, but to be markedly cleaved by
caspase-3 and, to a very small extent, by caspase-7. This
clearly shows a very strong selectivity of the probes for
caspase-3 in vitro, although one cannot fully exclude the
possible contribution of other caspases, especially caspase-7.
In order to test for the in vitro biological activity
of the probes, we ﬁrst developed a cellular model of
apoptosis by using staurosporine. Both ﬂow cytometry
andimmunoﬂuorescenceresultsdemonstratedtheapoptotic
eﬀect of staurosporine and its ability to activate caspase-3 in
HME cells. These resultsare in agreement with data reported
previously in various cell types [27–29]. They suggest that
this cell model is appropriate for the validation of probes
directed toward caspase-3.
Using this model, we found that lysates from apoptotic
endothelialcellseﬃcientlyactivated thethree probes,leading
to increased ﬂuorescence from the cleaved probe. Moreover,
this increased ﬂuorescence was strongly reduced in the
presence of a caspase-3 inhibitor, suggesting that it reﬂects
selective cleavage of the probes by caspase-3. In parallel,
we found a strong colocalization of the ﬂuorescent signal
with that originating from an antibody recognizing active
caspase-3.Thissuggeststhattheincreasedprobeﬂuorescence
selectively originates from cells with activated caspase-3.
Surprisingly, the caspase-3 inhibitor did not completely
reduce the signal originating from the antibody directed
against caspase-3 activity. This persistence in a context of an
abolition of the increased activity may be explained by the
epitopeofmAbagainst activated caspase-3, which recognizes
the terminal residues adjacent to Asp175 that is not located
directly in the enzymatic site of the protein, leading to
residualmAbbindingeveninthepresenceofblockedactivity
[30, 31].
The ﬁrst generation probe, QCASP3.2, demonstrated a
satisfactory capacity to be cleaved and to become ﬂuorescent
in the presence of activated caspase-3 (either recombinant
or endogenous); however, this probe resulted in a poor cell
labeling in ﬂow cytometry experiments (data not shown).
Since this was most likely due to insuﬃcient internalization
of the probe into cells, our next objective was to improve
the capacity of the probes to penetrate into cells, by adding
an α-helix polyarginine CPP (in QCASP4.1 and QCASP5.1
probes). Moreover, since incorporation of a PEG spacer
to peptide- or polymer-based architectures signiﬁcantly
increases circulation times [32, 33], we decided to incorpo-
rate a PEG moiety additionally to the CPP (in QCASP5.1
probe).
Weﬁrst demonstratedthattheadditionofCPPimproved
cellular penetration for both probes, although this was not
as pronounced with QCASP5.1, compared to QCASP4.1,
presumablyreﬂecting thefactthatthePEGmoietyhampered
cell penetration. The lower cell penetration of QCASP5.1,
compared to QCASP4.1 may also explain at least in part
the lower colocalization with caspase-3, as mentioned in the
results. It must be noted, however, that these experiments
were successful only when performed in nonapoptotic cells.
Indeed, the same experiment performed in staurosporine-
treated cells gave inconsistent results because a large part
of the apoptotic cells did not adhere to the culture dish,
rendering the separation between cells and medium almost
impossible. The diﬀerencesin cell penetration cannot be due
to diﬀerent binding to the cell membrane, since cell cultures
are trypsinized and washed before being lysed and incubated
with recombinant caspase-3 [34, 35].
As anticipated from the diﬀerences in cell penetration,
unlike QCASP3.2, the second-generation probes gave satis-
factory results in ﬂow cytometry, as demonstrated by the
marked increase in the percentage of positive cells after
treatment with staurosporine, and the abolition of this eﬀect
by the selective caspase-3 inhibitor.12 International Journal of Molecular Imaging
We also compared the ability of QCASP4.1 and
QCASP5.1to detect apoptosis by ﬂow cytometry with that of
annexin V. Although it may be limited by unspeciﬁc eﬀects
[13], annexin V is still a widely used and standard marker of
early apoptosis [36], since it is a natural ligand of PS which is
translocatedatthesurfaceofapoptoticcells.Thismechanism
occurs upon procaspase-3 activation [37]. These results with
annexin V are quantitatively similar to those obtained for
caspase-3activity,bothintermsoftheeﬀectofstaurosporine
and caspase-3 inhibitor. It must be noted that these similar
quantitative data were obtained in a relatively pure model
of apoptosis, thus this does not exclude the possibility that
annexin V may overestimate apoptotic cell death in other
more integrated models, especially in the presence of mixed
apoptotic and necrotic cell death.
Based on these positive results obtained in vitro, our
next step was to assess the capacity of the second-generation
probes to detect apoptosis ex vivo, in a pathologically
relevantmodelofcardiacapoptosis.Forthispurpose,cardiac
apoptosis was induced in vivo by doxorubicin (DOX). DOX
is an anthracycline commonly used in cancer chemotherapy,
and is well known for its capacity to induce cardiac oxidative
stress and apoptosis [23], leading to cardiomyopathy and
heart failure. Indeed, we conﬁrmed that DOX was associated
with an increased caspase-3 activity, suggesting that this
model is appropriate for the evaluation of the probes.
We ﬁrst measured the capacity of LV lysates to cleave
probes ex vivo. These results demonstrate the ability of
both probes to detect apoptosis via a caspase-3 mechanism;
however, this cleavage appeared much less pronounced
with QCASP4.1 than with QCASP5.1. As a result, we
failed to detect a signiﬁcant signal originating from cleaved
QCASP4.1 in cardiac tissue sections. Thus, only the data
obtained with QCASP5.1 are shown.
We ﬁnally found that cardiac apoptosis (induced by
DOX), was associated with a signiﬁcant increase in ﬂuores-
cence originating from cleaved QCASP5.1, which was also
prevented by the caspase-3 inhibitor, and which paralleled
the increased caspase-3 activity. Thus, taken together, these
results suggest that QCASP5.1 may eﬃciently and selectively
detect caspase-3 activity ex vivo in a clinically relevant model
of cardiac apoptosis.
5.Conclusion
In this study, we successfully validated cleavable optical
bioprobes that can be selectively activated by caspase-3 in
both in vitro and ex vivo models of cardiovascular apoptosis.
They thus may form new original tools for the detection
of apoptosis not only in cardiovascular diseases but also
possibly in cancer or immunoinﬂammatory diseases.
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